ALPS Advisors
SPTX icon

ALPS Advisors’s Seaport Therapeutics SPTX Stock Holding History

ALPS Advisors’s Portfolio SPTX Stock Details SPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.43M Buy
70,921
+16,593
+31% +$369K 0.01% 607
2026
Q2 		$1.18M Buy
+54,328
New +$956K 0.01% 656

Other funds holding SPTX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

ALPS Advisors's SPTX Position: Q3 2026 in Review

ALPS Advisors increased its Seaport Therapeutics (SPTX) stake by 31% in Q3 2026, buying an estimated $369K and bringing the position to 70,921 shares worth $1.43M. The position accounts for 0.01% of the portfolio, ranked #607.

ALPS Advisors first reported a position in SPTX in Q2 2026 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold SPTX as of Q3 2026.

  • ALPS Advisors held 70,921 shares of Seaport Therapeutics worth $1.43M as of Q3 2026.
  • ALPS Advisors bought 16,593 Seaport Therapeutics shares in Q3 2026, an estimated $369K.
  • Seaport Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q3 2026, its #607 holding.
  • ALPS Advisors first reported a position in Seaport Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held Seaport Therapeutics as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.